Acorda Therapeutics Announces Completion Of Zanaflex Capsules(TM) Sales Force Expansion

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc.® (Nasdaq: ACOR) reported today that it has completed the previously announced expansion of its sales force to 65 people, 52 of whom are area business managers calling on specialist and primary care physicians. The Acorda sales team promotes Zanaflex Capsules (tizanidine hydrochloride).

Back to news